NATCO Pharma Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NATCOPHARM.NS | IPCALAB.NS | GRANULES.BO | SHILPAMED.NS | 000597.SZ | IOLCP.NS | |
|---|---|---|---|---|---|---|
| Market cap | 156.27B | 494.62B | 192.80B | 184.68B | 6.41B | 55.51B |
| P/E (TTM) | 12.6 | 37.8 | 35.3 | 66.7 | 34.5 | 27.3 |
| Forward P/E | 16.8 | 27.7 | 26.5 | 45.3 | — | 17.5 |
| Price/book | 1.5 | 6.1 | 4.8 | 7.1 | 1.2 | 2.9 |
| Dividend yield | 0.75% | 0.30% | 0.26% | 0.06% | 1.23% | 0.54% |
| 1-year change | −4.67% | +51.13% | +0.63% | +160.71% | −20.28% | +87.93% |
| Today | +1.00% | −1.14% | −0.01% | +1.41% | +0.22% | +2.91% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All NATCOPHARM.NS news ›Natco Pharma closes Rs.12,794 million rights issue
Natco Pharma Limited completes Rs.12,794 million rights issue, closing on October 22, 2026, after the board's approval in September. Natco Pharma closes Rs.12,794 million rights issue Natco Pharma Limited, the renowned pharmaceutical…
Natco Pharma launches generic cancer drug Carboplatin in US
Drug maker Natco Pharma on Monday announced the launch of Carboplatin Injection in the US market through its subsidiary Natco Pharma USA LLC. The product, a generic version of Paraplatin, has been launched in manufacturing collaboration…
Natco Pharma Ltd. Rights Issue: Price, Record Date, Entitlement Ratio And Key Details
Learn the steps & benefits of opening a 3-in-1 account Made by experts, it covers everything about stock market Get to know ways to check IPO allotment status Link ICICI Bank Account to avail 3-in-1 account benefits Earn interest on unused…
Natco Pharma Ltd. 52 Week Low Streak: key stock context
Natco Pharma Ltd. 52 Week Low Streak has now extended to a second straight session, with the stock trading within 2% of its 52-week low across both days. Across the streak, the share price has moved down 2.23%, and the latest trading print…
NATCO Pharma Raises Investment in eGenesis to $16.70 Mn
NATCO Pharma Limited has increased its proposed investment in US-based biotechnology company eGenesis, Inc. to $16.70 million from the previously announced $14 million, according to a regulatory filing. The investment will be made through…
From the 4Search news index, newest first.